Integrated genomic, epigenomic and transcriptomic studies have provided insightful understanding of the tumorigenesis of pediatric DIPG, which also might hold promise for future utilization of molecular marker-driven clinical trials and use of novel targeted therapies such as HDAC, JMJD3, ACVR1, PPM1D, and BET bromodomain inhibitors, and CDK7 blockade40–44. The gene discussed is KDM6B; the disease is diffuse intrinsic pontine glioma.